Applicability of Adipose-Derived Stem Cells in Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is a form of early onset diabetes mellitus characterized by the autoimmune destruction of insulin-producing cells (IPCs), resulting in hyperglycemia and abnormal glucose metabolism. There are currently no treatments available capable of completely curing the symptoms...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2015-03-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.3727/096368915X686977 |
id |
doaj-a0da05d31fd64b42ac32cdb707ee99c8 |
---|---|
record_format |
Article |
spelling |
doaj-a0da05d31fd64b42ac32cdb707ee99c82020-11-25T03:52:03ZengSAGE PublishingCell Transplantation0963-68971555-38922015-03-012410.3727/096368915X686977Applicability of Adipose-Derived Stem Cells in Type 1 Diabetes MellitusHui-Ping Lin0Tzu-Min Chan1Ru-Huei Fu2Chih-Pin Chuu3Shao-Chih Chiu4Yu-Hsiung Tseng5Shih-Ping Liu6Kuang-Chi Lai7Mu-Chin Shih8Zung-Sheng Lin9Hsin-Shui Chen10Da-Chuan Yeh M.D.11Shinn-Zong Lin M.D., Ph.D.12 National Institute of Cancer Research, National Health Research Institutes, Miaoli, TaiwanDepartment of Medical Education and Research, China Medical University-An-Nan Hospital, Tainan, Taiwan Graduate Institute of Immunology, China Medical University, Taichung, Taiwan Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli, Taiwan Graduate Institute of Immunology, China Medical University, Taichung, Taiwan Department of Nephrology, China Medical University Beigan Hospital, Yunlin, Taiwan Department of Social Work, Asia University, Taichung, Taiwan School of Medicine, China Medical University, Taichung, Taiwan Department of Clinical Laboratory, China Medical University-An-Nan Hospital, Tainan, Taiwan Department of Surgery, China Medical University Beigan Hospital, Yunlin, Taiwan Department of Physical Medicine and Rehabilitation, China Medical University Beigang Hospital, Yunlin, Taiwan Department of Internal Medicine, China Medical University Beigan Hospital, Yunlin, Taiwan Department of Neurosurgery, China Medical University-An-Nan Hospital, Tainan, TaiwanType 1 diabetes mellitus (T1DM) is a form of early onset diabetes mellitus characterized by the autoimmune destruction of insulin-producing cells (IPCs), resulting in hyperglycemia and abnormal glucose metabolism. There are currently no treatments available capable of completely curing the symptoms associated with the loss or functional defects of IPCs. Nonetheless, stem cell therapy has demonstrated considerable promise in the replacement of IPCs with immunomodulatory functions to overcome the defects caused by T1DM. Adipose-derived stem cells (ADSCs) are particularly suitable for use in cell transplantation therapy, especially when seeking to avoid the ethical issues and tumorigenic complications commonly associated with embryos or induced pluripotent stem cells. Cell-based treatments have demonstrated therapeutic advantages and clinical applicability of ADSCs in T1DM, ensuring their suitability for transplantation therapy. This manuscript focuses on the benefits and possible mechanisms in a T1DM-relevant model and displays positive results from finished or ongoing human clinical trials. We also discuss and hypothesize potential methods to further enhance the therapeutic efficacy of these efforts, such as a humanized rodent model and gene therapies for IPC clusters, to meet the clinical applicability of the standard.https://doi.org/10.3727/096368915X686977 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hui-Ping Lin Tzu-Min Chan Ru-Huei Fu Chih-Pin Chuu Shao-Chih Chiu Yu-Hsiung Tseng Shih-Ping Liu Kuang-Chi Lai Mu-Chin Shih Zung-Sheng Lin Hsin-Shui Chen Da-Chuan Yeh M.D. Shinn-Zong Lin M.D., Ph.D. |
spellingShingle |
Hui-Ping Lin Tzu-Min Chan Ru-Huei Fu Chih-Pin Chuu Shao-Chih Chiu Yu-Hsiung Tseng Shih-Ping Liu Kuang-Chi Lai Mu-Chin Shih Zung-Sheng Lin Hsin-Shui Chen Da-Chuan Yeh M.D. Shinn-Zong Lin M.D., Ph.D. Applicability of Adipose-Derived Stem Cells in Type 1 Diabetes Mellitus Cell Transplantation |
author_facet |
Hui-Ping Lin Tzu-Min Chan Ru-Huei Fu Chih-Pin Chuu Shao-Chih Chiu Yu-Hsiung Tseng Shih-Ping Liu Kuang-Chi Lai Mu-Chin Shih Zung-Sheng Lin Hsin-Shui Chen Da-Chuan Yeh M.D. Shinn-Zong Lin M.D., Ph.D. |
author_sort |
Hui-Ping Lin |
title |
Applicability of Adipose-Derived Stem Cells in Type 1 Diabetes Mellitus |
title_short |
Applicability of Adipose-Derived Stem Cells in Type 1 Diabetes Mellitus |
title_full |
Applicability of Adipose-Derived Stem Cells in Type 1 Diabetes Mellitus |
title_fullStr |
Applicability of Adipose-Derived Stem Cells in Type 1 Diabetes Mellitus |
title_full_unstemmed |
Applicability of Adipose-Derived Stem Cells in Type 1 Diabetes Mellitus |
title_sort |
applicability of adipose-derived stem cells in type 1 diabetes mellitus |
publisher |
SAGE Publishing |
series |
Cell Transplantation |
issn |
0963-6897 1555-3892 |
publishDate |
2015-03-01 |
description |
Type 1 diabetes mellitus (T1DM) is a form of early onset diabetes mellitus characterized by the autoimmune destruction of insulin-producing cells (IPCs), resulting in hyperglycemia and abnormal glucose metabolism. There are currently no treatments available capable of completely curing the symptoms associated with the loss or functional defects of IPCs. Nonetheless, stem cell therapy has demonstrated considerable promise in the replacement of IPCs with immunomodulatory functions to overcome the defects caused by T1DM. Adipose-derived stem cells (ADSCs) are particularly suitable for use in cell transplantation therapy, especially when seeking to avoid the ethical issues and tumorigenic complications commonly associated with embryos or induced pluripotent stem cells. Cell-based treatments have demonstrated therapeutic advantages and clinical applicability of ADSCs in T1DM, ensuring their suitability for transplantation therapy. This manuscript focuses on the benefits and possible mechanisms in a T1DM-relevant model and displays positive results from finished or ongoing human clinical trials. We also discuss and hypothesize potential methods to further enhance the therapeutic efficacy of these efforts, such as a humanized rodent model and gene therapies for IPC clusters, to meet the clinical applicability of the standard. |
url |
https://doi.org/10.3727/096368915X686977 |
work_keys_str_mv |
AT huipinglin applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT tzuminchan applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT ruhueifu applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT chihpinchuu applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT shaochihchiu applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT yuhsiungtseng applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT shihpingliu applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT kuangchilai applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT muchinshih applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT zungshenglin applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT hsinshuichen applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT dachuanyehmd applicabilityofadiposederivedstemcellsintype1diabetesmellitus AT shinnzonglinmdphd applicabilityofadiposederivedstemcellsintype1diabetesmellitus |
_version_ |
1724484660336001024 |